Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Gland Pharma: Analyzing customer concentration risk

26 May 2023 , 11:20 AM

Recommendation: Reduce

Target Price: Rs. 1,000

Sagent Pharma, Athenex and Eversana accounted for 20% of Gland’s overall shipments in FY23, where there could be risk of further business loss as Sagent/Athenex have been undergoing challenges and/or have gone bankrupt. Further loss of business from these customers would pose a downside risk to IIFL’s assumption of 11-12% revenue CAGR and 28-30% EBITDA margins for Gland’s base business over FY23-26. The stock is trading at 15x FY25 PE which is fair (not cheap), given the inherent volatility in export businesses and structural downward reset in Gland’s growth rates from 20% to 11-12%, post the Cenexi acquisition.

Sagent acquired by Gland’s ex-promoter while Athenex is under bankruptcy

Gland’s export shipments to Sagent averaged USD44 million over FY20-22, but have declined to USD22 million in FY23 as Sagent has been ongoing through operational challenges and was recently acquired by Gland’s ex-promoter. Undergoing Chapter-11 bankruptcy, Athenex accounted for USD22 million of Gland’s export shipments in FY23. While management has indicated that they expect to retain business from these customers, Sagent & Athenex together contributed 13% to Gland’s FY23 exports (versus 16-17% in FY21/22), which could potentially be at risk.

Eversana becomes a big customer in FY23, but not much info available

Gland’s shipments to Eversana were USD1-3 million over FY20-22 but increased to USD20 million in FY23, and sustainability of this needs to be watched out. Analysts at IIFL Securities were not able to find much info on Eversana except that it is a Managed Services provider for Life Sciences companies and that Eversana used to manage Athenex’s US product distribution/customer engagement. Hence, given Eversana’s relationship with Athenex, Gland’s revenue from the latter could exceed its direct exposure of USD22 million.

Sagent, Athenex and Eversana contributed 20% to Gland’s exports

Further revenue loss from these customers is not factored into IIFL’s estimates and will pose downside risks to their assumption of 11-12% revenue CAGR and 28-30% margins for Gland’s base business over FY23-26.

Related Tags

  • Gland Pharma
sidebar mobile


Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account." is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.